Next-generation medicine

Combining BCR-ABL and hedgehog-targeted therapies

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

Original languageEnglish (US)
Pages (from-to)1309-1311
Number of pages3
JournalClinical Cancer Research
Volume19
Issue number6
DOIs
StatePublished - Mar 15 2013

Fingerprint

Leukemia
Medicine
Cause of Death
Phosphotransferases
Stem Cells
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Next-generation medicine : Combining BCR-ABL and hedgehog-targeted therapies. / Dao, Kim-Hien; Tyner, Jeffrey.

In: Clinical Cancer Research, Vol. 19, No. 6, 15.03.2013, p. 1309-1311.

Research output: Contribution to journalArticle

@article{0b8b87bfe7084ee98e3ee287565b1cb3,
title = "Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies",
abstract = "Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.",
author = "Kim-Hien Dao and Jeffrey Tyner",
year = "2013",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-12-3934",
language = "English (US)",
volume = "19",
pages = "1309--1311",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Next-generation medicine

T2 - Combining BCR-ABL and hedgehog-targeted therapies

AU - Dao, Kim-Hien

AU - Tyner, Jeffrey

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

AB - Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

UR - http://www.scopus.com/inward/record.url?scp=84875208239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875208239&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-3934

DO - 10.1158/1078-0432.CCR-12-3934

M3 - Article

VL - 19

SP - 1309

EP - 1311

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -